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Principles of therapeutic drug monitoring: a case of drug-resistant 
epilepsy in a dog 
 
Robert T. Kinobe & Ninette Keller, School of Veterinary and Biomedical Sciences, James Cook 
University, Solander Drive Douglas, 4811 QLD Australia 
 
Drug analysis for purposes of monitoring therapeutic outcomes is not a common practice in veterinary 
medicine but may be extremely valuable in many circumstances including; clinical cases in which 
there is a poor correlation between dose and drug plasma concentration, and therapeutic or toxic 
effects, confirmation of drug-induced toxicity for medications with very low therapeutic indices, 
assessment of compliance with the drug administration and assessing the occurrence of drug-drug 
interactions. Therapeutic drug monitoring may also be indicated for patients with altered 
physiological states such as renal, thyroid and hepatic disease, and electrolyte imbalances. In this 
article, a clinical case of canine idiopathic epilepsy with an apparent resistance to antiepileptic drug 
therapy is used to illustrate some of the basic principles of therapeutic drug monitoring (TMD). 
 
Case report: history, clinical presentation and treatment 
Two years ago, a 4-year-old, male Staffordshire bull terrier, 24 Kg, was diagnosed with idiopathic 
epilepsy with a history of tonic-clonic seizures (~3 seizures per month). The seizures were 
characterised by facial automatisms, forelimb clonus, falling and loss of consciousness. Therapy was 
initiated with phenobarbitone 2.5 mg/Kg PO BID and the dose had been escalated and stabilised at 7 
mg/kg PO BID for several months. The patient begun seizuring more frequently (~ 1 seizure per week) 
and was presented to James Cook veterinary hospital in status epilepticus and dilated pupils that did 
not respond to light. The referring doctor had administered 1 mg/kg diazepam but no response was 
observed. The patient was sedated with boluses of 20 mg of propofol at a time, and was also given 5 
mg/Kg phenobarbitone intravenously BID, 0.005 mg/Kg/min midazolam over 6 hours, 4 mg/Kg 
furosemide intravenously and 1 gram/Kg of mannitol slowly intravenously over 30 minutes.  
 
Blood analysis revealed no detectable abnormalities and Phenobarbital levels were within therapeutic 
range. The rest of the neurological examination could not be performed because of anaesthetics. 
Oxygen saturation (SPO2) was estimated at 88% and oxygen supplementation was instituted. The 
animal did not seizure again, had normal papillary light responses and did not appear to be blind. The 
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immediate concerns were the recurrence of frequent and severe convulsions. As a result, plans were 
made to send the patient home with strong considerations of the application of the principles of 
therapeutic drug monitoring. In addition, magnetic resonance imaging of the brain and spinal cord 
was sought.  
 
 
What principles of TDM are applicable to the use of phenobarbitone in this case? 
When to institute TDM, when and how to sample blood for drug analysis:  
Many drugs may be used to treat canine idiopathic epilepsy but phenobarbitone and potassium 
bromide are the most commonly prescribed for this condition.1-2 However, both phenobarbitone and 
the bromide have variable pharmacokinetic profiles in different dogs and each individual animal may 
show variable rates of absorption, distribution, metabolism and excretion. This results in variable 
serum drug concentrations even at recommended dose rates (2-4 mg/kg body weight per day divided 
into q8 or 12h) for phenobarbitone.3-4 The average half-life (T1/2) of phenobarbitone is 53 hr (32-75 hr) 
and with repeated dosing at intervals shorter than the half-life, the drug accumulates until “steady 
state” is attained. At steady state, drug intake equilibrates with elimination by metabolism and 
excretion and serum drug concentrations will only fluctuate between given limits of minimum (Cmin-
troughs) and maximum (Cmax-peaks). It takes ~5-6 half-lives to attain 99% of steady-state serum drug 
concentrations and in the case of phenobarbitone (T1/2 = 53 hr), TDM may be instituted 11-14 days 
after the initiation of therapy. If T1/2 is markedly shorter (< 24 hours) with the accompanying lack of 
efficacy, peak (4-5 hr after dosing) and trough serum concentrations (taken just before the next dose) 
could be measured to ascertain the exact T1/2 and an appropriate dosing interval. This procedure is 
illustrated in Figure 1 below. For animals with T1/2 of phenobarbitone < 24 hr, dosing every 8 hours 
may improve seizure control. Either serum or plasma sampled any time during the dosing interval 
could consistently be used for drug analysis because phenobarbitone has a relatively long half-life 
implying that variations between peaks and troughs are minimised. It is important to remember to 
avoid using serum-separator tubes because they decrease drug concentrations by adsorption of drug 
into the matrix.5  
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Another important pharmcodynamic feature of phenobarbitone is its ability to induce the expression 
of cytochrome P450 enzymes (CYP2B11, CYP3A12 & CYP4A) via the retinoid receptor in hepatocytes 
and other tissues.6 These functionalisation phase-1 enzymes are involved in the metabolism and 
clearance of this drug thus with repeated dosing, the metabolic clearance of phenobarbitone is 
markedly enhanced and this may alter steady state serum concentrations. Typically, significant 
enzyme induction is detected 8-12 weeks after the initiation of therapy and routine monitoring is 
done every 6 months.3 On the other hand, marked elevation of serum phenobarbitone concentrations 
is associated with hepatotoxicity characterised by increased serum concentrations of alkaline 
phosphatase and alanine transaminase.7 As a consequence, hepatotoxicity will often limit the clinical 
use of phenobarbitone in chronic conditions and it usually recommended to add bromide therapy 
before reaching the upper limits of the therapeutic range.7     
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Interpretation of results of therapeutic drug monitoring:  
Normal therapeutic serum concentrations of phenobarbitone are dependent on whether the patient is 
receiving monotherapy or drug combinations. For dogs on phenobarbitone only, 65-175 μmoles/L is 
recommended while for a combination of phenobarbitone and potassium bromide, 43-155 μmoles/L of 
phenobarbitone and 10-20 mmol/L (1-2 mg/mL) of the bromide are believed to be within the 
therapeutic range.4 Phenobarbitone may be reduced or removed from seizure therapy once the 
bromide (T1/2 = 24 days), has attained steady state (~ 4 months). Typically the phenobarbitone dose is 
reduced by 10-25% every 4-6 weeks and the bromide is maintained at a serum concentration of 30 
mmol/L.8 To circumvent the problem associated with longer waiting periods to establish steady state, 
loading doses are usually given in dogs with severe and frequent seizures to allow for the rapid switch 
from one drug to another. A loading dose is intended to fully occupy the apparent volume of 
distribution of the drug to achieve a target, recommended therapeutic serum concentration (1-2 
mg/mL). The apparent volume of distribution of potassium bromide is (0.2-0.4 L/Kg). So for the 24 
Kg male dog described here, the recommended loading dose was evaluated as illustrated in figure 2 
below. 
  










An oral loading dose of 600 mg/Kg of potassium bromide was divided into 5 doses, mixed with food 
and given over 5 days SID, followed by an initial maintenance dose of 30 mg/kg PO once daily. 
Typically a maintenance dose is based on the target plasma concentration and the clearance of a 
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particular drug. This dosing regimen was consistent with standard recommended doses for potassium 
bromide in treating idiopathic epilepsy.1 Steady- state serum concentrations with the bromide were 
established and phenobarbitone was withdrawn. The patient stabilised for three months but suffered 
massive breakthrough seizures and because of the deteriorating quality of life and the cost of 
treatment he was euthanized.      
 
Dose adjustment and increasing target serum drug concentration of an antiepileptic drug:  
At the initiation of therapy, the patient described here received phenobarbitone at a rate of 2.5 mg/Kg 
PO BID and the dose had been escalated and stabilised at 7 mg/kg PO BID for several months. This 
section examines standard considerations and approaches in using TDM in adjusting the patient’s 
dosing regimen. The first dosing rate (2.5 mg/Kg PO BID), yielded an average peak and trough serum 
phenobarbitone concentration (60 μmoles/L) below the recommended therapeutic range. 
Subsequently, we aimed to elevate the average serum concentrations to 170 μmoles/L. What should 
have been the corresponding adjusted dosing rate? 
 
It is important to note that phenobarbitone serum drug concentrations exceeding 180 μmoles/L may 
manifest in toxicity characterised by excessive sedation, ataxia, elevated alkaline phosphatase and 
hepatotoxicity, blood dyscrasias and polyphagia. Under these circumstances, phenobarbitone therapy 
alone may be inadequate and switching to other drugs may be recommended. Recent studies have 
documented the clinical use of other medications including primidone, levetiracetam, gabapentin, 
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